| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 370 | 2025 | 6982 | 22.150 |
Why?
|
| Aspirin | 93 | 2024 | 3135 | 12.440 |
Why?
|
| Diverticulitis | 16 | 2024 | 187 | 7.950 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 51 | 2024 | 2277 | 5.230 |
Why?
|
| Diet | 86 | 2024 | 8090 | 5.110 |
Why?
|
| Colitis, Ulcerative | 37 | 2024 | 1931 | 5.040 |
Why?
|
| Adenoma | 49 | 2023 | 2164 | 4.950 |
Why?
|
| Dietary Fiber | 23 | 2024 | 767 | 4.610 |
Why?
|
| Crohn Disease | 35 | 2024 | 2297 | 4.480 |
Why?
|
| Prospective Studies | 286 | 2025 | 54950 | 3.800 |
Why?
|
| Anticarcinogenic Agents | 10 | 2018 | 251 | 3.340 |
Why?
|
| Risk Factors | 316 | 2025 | 74971 | 3.210 |
Why?
|
| Carcinoma, Hepatocellular | 28 | 2024 | 2336 | 3.140 |
Why?
|
| Colonic Polyps | 22 | 2023 | 557 | 3.080 |
Why?
|
| Microsatellite Instability | 42 | 2024 | 726 | 2.860 |
Why?
|
| Colonic Neoplasms | 35 | 2023 | 2543 | 2.860 |
Why?
|
| Liver Neoplasms | 33 | 2024 | 4363 | 2.790 |
Why?
|
| Colonoscopy | 27 | 2025 | 1410 | 2.660 |
Why?
|
| Proton Pump Inhibitors | 9 | 2024 | 553 | 2.650 |
Why?
|
| Follow-Up Studies | 161 | 2024 | 39394 | 2.610 |
Why?
|
| Vitamin D | 26 | 2023 | 3311 | 2.510 |
Why?
|
| Middle Aged | 422 | 2025 | 223740 | 2.360 |
Why?
|
| Feces | 16 | 2024 | 1511 | 2.360 |
Why?
|
| Incidence | 111 | 2025 | 21545 | 2.330 |
Why?
|
| Gastroesophageal Reflux | 6 | 2023 | 836 | 2.320 |
Why?
|
| Sigmoidoscopy | 6 | 2022 | 150 | 2.290 |
Why?
|
| Diverticulitis, Colonic | 5 | 2021 | 139 | 2.280 |
Why?
|
| Proportional Hazards Models | 90 | 2024 | 12563 | 2.270 |
Why?
|
| Gallstones | 7 | 2024 | 285 | 2.250 |
Why?
|
| Humans | 736 | 2025 | 768887 | 2.230 |
Why?
|
| Polymorphism, Single Nucleotide | 102 | 2024 | 16051 | 2.230 |
Why?
|
| Vegetables | 13 | 2024 | 1199 | 2.170 |
Why?
|
| Cyclooxygenase 2 | 15 | 2020 | 599 | 2.160 |
Why?
|
| Genetic Predisposition to Disease | 89 | 2024 | 18065 | 2.150 |
Why?
|
| Life Style | 28 | 2024 | 3931 | 2.110 |
Why?
|
| Feeding Behavior | 26 | 2021 | 3206 | 2.100 |
Why?
|
| Aged | 337 | 2024 | 171790 | 2.090 |
Why?
|
| Nurses | 34 | 2023 | 2501 | 2.080 |
Why?
|
| Female | 506 | 2025 | 397464 | 2.040 |
Why?
|
| Case-Control Studies | 115 | 2024 | 22294 | 1.890 |
Why?
|
| Early Detection of Cancer | 19 | 2025 | 3238 | 1.860 |
Why?
|
| Fruit | 12 | 2024 | 1165 | 1.800 |
Why?
|
| Adult | 317 | 2025 | 223818 | 1.790 |
Why?
|
| Gastroenterology | 6 | 2024 | 593 | 1.740 |
Why?
|
| Inflammatory Bowel Diseases | 18 | 2023 | 2445 | 1.710 |
Why?
|
| Male | 407 | 2025 | 365249 | 1.700 |
Why?
|
| Sulfur | 3 | 2021 | 158 | 1.630 |
Why?
|
| United States | 155 | 2025 | 73180 | 1.590 |
Why?
|
| Hyperinsulinism | 6 | 2024 | 402 | 1.550 |
Why?
|
| Sulfur-Reducing Bacteria | 2 | 2021 | 14 | 1.550 |
Why?
|
| Fatty Acids, Omega-3 | 9 | 2022 | 1399 | 1.540 |
Why?
|
| Chemoprevention | 8 | 2022 | 326 | 1.510 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 11 | 2017 | 321 | 1.500 |
Why?
|
| Obesity | 41 | 2024 | 13087 | 1.470 |
Why?
|
| Proto-Oncogene Proteins B-raf | 33 | 2023 | 2059 | 1.460 |
Why?
|
| Body Mass Index | 65 | 2024 | 13054 | 1.460 |
Why?
|
| Risk Assessment | 88 | 2024 | 24330 | 1.460 |
Why?
|
| Vitamins | 11 | 2024 | 1638 | 1.450 |
Why?
|
| Genome-Wide Association Study | 66 | 2024 | 12798 | 1.410 |
Why?
|
| Cohort Studies | 99 | 2024 | 41800 | 1.400 |
Why?
|
| Smoking | 38 | 2024 | 9094 | 1.390 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 16 | 2024 | 1105 | 1.360 |
Why?
|
| Stomach Neoplasms | 5 | 2024 | 1483 | 1.330 |
Why?
|
| Defecation | 4 | 2023 | 191 | 1.300 |
Why?
|
| CpG Islands | 25 | 2023 | 1210 | 1.300 |
Why?
|
| Mendelian Randomization Analysis | 19 | 2024 | 1040 | 1.280 |
Why?
|
| Gastrointestinal Hemorrhage | 7 | 2020 | 1126 | 1.260 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2024 | 1813 | 1.260 |
Why?
|
| Multivariate Analysis | 46 | 2020 | 12093 | 1.250 |
Why?
|
| Adiponectin | 10 | 2024 | 1117 | 1.240 |
Why?
|
| Fecal Incontinence | 4 | 2022 | 246 | 1.240 |
Why?
|
| Fusobacterium nucleatum | 11 | 2024 | 176 | 1.240 |
Why?
|
| Meat | 7 | 2024 | 588 | 1.230 |
Why?
|
| Anti-Bacterial Agents | 11 | 2024 | 7472 | 1.200 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 5 | 2023 | 388 | 1.190 |
Why?
|
| Contraceptives, Oral | 6 | 2018 | 560 | 1.180 |
Why?
|
| Adenomatous Polyps | 4 | 2021 | 109 | 1.170 |
Why?
|
| Glutens | 5 | 2021 | 240 | 1.090 |
Why?
|
| Estrogen Replacement Therapy | 9 | 2024 | 1209 | 1.080 |
Why?
|
| C-Reactive Protein | 14 | 2024 | 3858 | 1.060 |
Why?
|
| Metabolome | 6 | 2024 | 1009 | 1.060 |
Why?
|
| Precancerous Conditions | 7 | 2024 | 985 | 1.050 |
Why?
|
| Adiposity | 11 | 2021 | 1895 | 1.020 |
Why?
|
| Dietary Supplements | 19 | 2024 | 3442 | 1.020 |
Why?
|
| Genetic Loci | 17 | 2024 | 2630 | 1.010 |
Why?
|
| Smad7 Protein | 3 | 2021 | 39 | 1.000 |
Why?
|
| Seafood | 4 | 2019 | 395 | 0.980 |
Why?
|
| Alcohol Drinking | 20 | 2024 | 4045 | 0.980 |
Why?
|
| Diet Surveys | 12 | 2021 | 1160 | 0.980 |
Why?
|
| Primary Prevention | 7 | 2022 | 1187 | 0.970 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2015 | 199 | 0.950 |
Why?
|
| Digestive System Neoplasms | 2 | 2021 | 82 | 0.940 |
Why?
|
| Neoplasms | 29 | 2024 | 22390 | 0.900 |
Why?
|
| Postmenopause | 11 | 2024 | 2519 | 0.890 |
Why?
|
| Metabolomics | 7 | 2024 | 1675 | 0.880 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2024 | 2763 | 0.880 |
Why?
|
| Personnel Selection | 2 | 2015 | 201 | 0.850 |
Why?
|
| Inflammation | 22 | 2024 | 10869 | 0.850 |
Why?
|
| Vitamin D Deficiency | 7 | 2022 | 1388 | 0.850 |
Why?
|
| Health Personnel | 19 | 2024 | 3382 | 0.850 |
Why?
|
| Health Surveys | 23 | 2021 | 4055 | 0.850 |
Why?
|
| Prognosis | 71 | 2023 | 30044 | 0.840 |
Why?
|
| Risk Reduction Behavior | 6 | 2020 | 1119 | 0.840 |
Why?
|
| Adenocarcinoma | 12 | 2022 | 6401 | 0.840 |
Why?
|
| Reproductive History | 3 | 2018 | 210 | 0.830 |
Why?
|
| Sex Hormone-Binding Globulin | 7 | 2022 | 554 | 0.820 |
Why?
|
| Rectal Neoplasms | 11 | 2022 | 1183 | 0.810 |
Why?
|
| Carcinoma | 10 | 2023 | 2340 | 0.810 |
Why?
|
| Cholecalciferol | 4 | 2015 | 557 | 0.810 |
Why?
|
| Multiple Sclerosis | 18 | 2023 | 3250 | 0.800 |
Why?
|
| Bacteria | 6 | 2023 | 2219 | 0.790 |
Why?
|
| Cardiovascular Diseases | 21 | 2024 | 15662 | 0.790 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2024 | 12252 | 0.780 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2013 | 361 | 0.780 |
Why?
|
| Odds Ratio | 42 | 2021 | 9682 | 0.780 |
Why?
|
| Iron, Dietary | 2 | 2017 | 148 | 0.770 |
Why?
|
| Coffee | 7 | 2024 | 594 | 0.760 |
Why?
|
| Inflammation Mediators | 6 | 2021 | 1890 | 0.760 |
Why?
|
| Sulfur Compounds | 1 | 2021 | 32 | 0.750 |
Why?
|
| DNA Methylation | 32 | 2023 | 4432 | 0.750 |
Why?
|
| Polypharmacy | 2 | 2021 | 307 | 0.710 |
Why?
|
| Tumor Microenvironment | 18 | 2024 | 3951 | 0.710 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2023 | 455 | 0.710 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2014 | 87 | 0.710 |
Why?
|
| Dinoprostone | 2 | 2020 | 597 | 0.710 |
Why?
|
| Periodicals as Topic | 2 | 2024 | 1470 | 0.700 |
Why?
|
| Exercise | 15 | 2023 | 5953 | 0.690 |
Why?
|
| Cognition | 5 | 2023 | 7080 | 0.690 |
Why?
|
| Logistic Models | 37 | 2024 | 13317 | 0.680 |
Why?
|
| Berberine | 1 | 2020 | 26 | 0.670 |
Why?
|
| Risk | 34 | 2023 | 9621 | 0.670 |
Why?
|
| Colitis, Microscopic | 4 | 2022 | 71 | 0.670 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 21 | 2023 | 1769 | 0.670 |
Why?
|
| Time Factors | 41 | 2024 | 40266 | 0.660 |
Why?
|
| Aged, 80 and over | 66 | 2024 | 59738 | 0.660 |
Why?
|
| Vitamin D-Binding Protein | 2 | 2020 | 130 | 0.650 |
Why?
|
| Gastrointestinal Diseases | 3 | 2017 | 1206 | 0.650 |
Why?
|
| Genotype | 40 | 2024 | 13048 | 0.650 |
Why?
|
| Tea | 2 | 2023 | 289 | 0.640 |
Why?
|
| Mutation | 46 | 2024 | 30266 | 0.640 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2023 | 256 | 0.630 |
Why?
|
| Celiac Disease | 3 | 2021 | 820 | 0.630 |
Why?
|
| Dietary Fats | 4 | 2020 | 2003 | 0.630 |
Why?
|
| DNA, Mitochondrial | 6 | 2020 | 871 | 0.620 |
Why?
|
| Masks | 1 | 2021 | 214 | 0.620 |
Why?
|
| ras Proteins | 7 | 2014 | 1058 | 0.620 |
Why?
|
| Tooth Loss | 4 | 2023 | 200 | 0.620 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 103 | 0.620 |
Why?
|
| Liver Cirrhosis | 6 | 2024 | 1962 | 0.610 |
Why?
|
| Folic Acid | 6 | 2024 | 1336 | 0.610 |
Why?
|
| Liver | 2 | 2024 | 7579 | 0.610 |
Why?
|
| Colon | 15 | 2021 | 1804 | 0.600 |
Why?
|
| Cholangiocarcinoma | 6 | 2020 | 562 | 0.600 |
Why?
|
| Leukocytes | 8 | 2022 | 2034 | 0.600 |
Why?
|
| C-Peptide | 10 | 2024 | 443 | 0.600 |
Why?
|
| Glucuronosyltransferase | 2 | 2011 | 136 | 0.600 |
Why?
|
| Sentinel Surveillance | 1 | 2020 | 292 | 0.600 |
Why?
|
| Diverticulosis, Colonic | 1 | 2017 | 9 | 0.600 |
Why?
|
| Bile Duct Neoplasms | 6 | 2019 | 615 | 0.600 |
Why?
|
| Weight Gain | 11 | 2023 | 2359 | 0.590 |
Why?
|
| Diverticulum, Colon | 1 | 2017 | 32 | 0.590 |
Why?
|
| Diet, Mediterranean | 7 | 2022 | 748 | 0.590 |
Why?
|
| Diphosphonates | 2 | 2013 | 634 | 0.580 |
Why?
|
| Interleukin-6 | 9 | 2024 | 3233 | 0.580 |
Why?
|
| Fatty Liver | 1 | 2024 | 810 | 0.570 |
Why?
|
| Sex Factors | 29 | 2024 | 10641 | 0.570 |
Why?
|
| Genetic Variation | 17 | 2021 | 6610 | 0.570 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2022 | 3253 | 0.570 |
Why?
|
| Diet Therapy | 1 | 2018 | 150 | 0.570 |
Why?
|
| Waist Circumference | 8 | 2024 | 935 | 0.560 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2009 | 246 | 0.560 |
Why?
|
| Long Interspersed Nucleotide Elements | 10 | 2023 | 332 | 0.560 |
Why?
|
| Metagenome | 5 | 2024 | 465 | 0.560 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 3116 | 0.560 |
Why?
|
| Telomere | 5 | 2022 | 943 | 0.550 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 3239 | 0.550 |
Why?
|
| Prostaglandins | 2 | 2017 | 398 | 0.550 |
Why?
|
| Sulfonamides | 3 | 2011 | 1982 | 0.540 |
Why?
|
| Metagenomics | 6 | 2024 | 474 | 0.540 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 15 | 2022 | 906 | 0.530 |
Why?
|
| Nursing Research | 1 | 2017 | 80 | 0.530 |
Why?
|
| Fellowships and Scholarships | 2 | 2015 | 1134 | 0.530 |
Why?
|
| Fish Oils | 2 | 2019 | 483 | 0.530 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 5 | 2016 | 348 | 0.530 |
Why?
|
| beta Catenin | 7 | 2020 | 1047 | 0.530 |
Why?
|
| Ethanol | 3 | 2019 | 1332 | 0.530 |
Why?
|
| Age Factors | 24 | 2023 | 18454 | 0.520 |
Why?
|
| Fluorouracil | 4 | 2020 | 1655 | 0.520 |
Why?
|
| Fluorocarbons | 1 | 2021 | 506 | 0.520 |
Why?
|
| Overweight | 6 | 2022 | 2445 | 0.520 |
Why?
|
| Pyrazoles | 3 | 2011 | 2029 | 0.510 |
Why?
|
| Exercise Therapy | 3 | 2018 | 938 | 0.510 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 622 | 0.510 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2022 | 241 | 0.510 |
Why?
|
| Motor Activity | 8 | 2015 | 2722 | 0.510 |
Why?
|
| Phosphatidylinositol 3-Kinases | 12 | 2021 | 2884 | 0.500 |
Why?
|
| Heme | 1 | 2017 | 316 | 0.490 |
Why?
|
| Physicians, Primary Care | 1 | 2022 | 625 | 0.490 |
Why?
|
| Antineoplastic Agents | 8 | 2024 | 13699 | 0.490 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2013 | 453 | 0.480 |
Why?
|
| Alcoholic Beverages | 1 | 2016 | 266 | 0.480 |
Why?
|
| Double-Blind Method | 15 | 2024 | 12469 | 0.480 |
Why?
|
| Molecular Epidemiology | 7 | 2019 | 473 | 0.470 |
Why?
|
| Receptors, Leptin | 2 | 2013 | 352 | 0.470 |
Why?
|
| Interferon-beta | 2 | 2015 | 349 | 0.470 |
Why?
|
| Calcium, Dietary | 4 | 2019 | 533 | 0.470 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2014 | 31 | 0.470 |
Why?
|
| Diet, Gluten-Free | 1 | 2017 | 284 | 0.460 |
Why?
|
| Age of Onset | 12 | 2021 | 3346 | 0.460 |
Why?
|
| Placebos | 5 | 2024 | 1668 | 0.460 |
Why?
|
| Data Collection | 2 | 2020 | 3322 | 0.450 |
Why?
|
| Drug Administration Schedule | 10 | 2018 | 4862 | 0.450 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2022 | 187 | 0.440 |
Why?
|
| Biomedical Research | 5 | 2024 | 3463 | 0.440 |
Why?
|
| Pathology, Molecular | 5 | 2017 | 329 | 0.440 |
Why?
|
| Neoplasm Staging | 27 | 2024 | 11262 | 0.430 |
Why?
|
| Population Surveillance | 7 | 2021 | 2597 | 0.430 |
Why?
|
| Itraconazole | 1 | 2013 | 43 | 0.430 |
Why?
|
| Progestins | 3 | 2022 | 302 | 0.420 |
Why?
|
| Barrett Esophagus | 2 | 2015 | 495 | 0.420 |
Why?
|
| Demography | 2 | 2015 | 1643 | 0.420 |
Why?
|
| Sweden | 11 | 2023 | 1382 | 0.420 |
Why?
|
| Seasons | 3 | 2016 | 1523 | 0.420 |
Why?
|
| Education, Medical, Graduate | 2 | 2015 | 2422 | 0.420 |
Why?
|
| Cladribine | 2 | 2022 | 34 | 0.410 |
Why?
|
| Cognition Disorders | 2 | 2017 | 3985 | 0.410 |
Why?
|
| Dairy Products | 3 | 2021 | 490 | 0.410 |
Why?
|
| Mass Screening | 9 | 2022 | 5455 | 0.410 |
Why?
|
| Disease-Free Survival | 8 | 2024 | 6856 | 0.410 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2012 | 58 | 0.410 |
Why?
|
| Proteomics | 7 | 2024 | 3913 | 0.410 |
Why?
|
| Periodontal Diseases | 3 | 2023 | 455 | 0.410 |
Why?
|
| Australia | 7 | 2024 | 1265 | 0.410 |
Why?
|
| Peptic Ulcer | 1 | 2014 | 215 | 0.410 |
Why?
|
| Cecal Neoplasms | 2 | 2012 | 27 | 0.410 |
Why?
|
| Gene Expression | 8 | 2022 | 7602 | 0.400 |
Why?
|
| T-Lymphocytes | 8 | 2019 | 10276 | 0.400 |
Why?
|
| Flavonoids | 3 | 2023 | 447 | 0.400 |
Why?
|
| Self Report | 13 | 2024 | 3773 | 0.400 |
Why?
|
| Genomics | 7 | 2022 | 5928 | 0.400 |
Why?
|
| HSP110 Heat-Shock Proteins | 1 | 2011 | 10 | 0.390 |
Why?
|
| Medical History Taking | 5 | 2019 | 779 | 0.390 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2024 | 4651 | 0.390 |
Why?
|
| Liver Diseases | 1 | 2020 | 1305 | 0.390 |
Why?
|
| Leptin | 3 | 2018 | 1597 | 0.380 |
Why?
|
| Rectum | 9 | 2020 | 900 | 0.380 |
Why?
|
| Constipation | 3 | 2023 | 570 | 0.380 |
Why?
|
| Zinc | 1 | 2015 | 678 | 0.380 |
Why?
|
| DNA Copy Number Variations | 5 | 2020 | 2055 | 0.380 |
Why?
|
| DNA Glycosylases | 2 | 2022 | 125 | 0.380 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2011 | 219 | 0.370 |
Why?
|
| Young Adult | 41 | 2024 | 60110 | 0.370 |
Why?
|
| ABO Blood-Group System | 2 | 2011 | 381 | 0.370 |
Why?
|
| Quantitative Trait Loci | 6 | 2024 | 2133 | 0.370 |
Why?
|
| Testosterone | 5 | 2022 | 2494 | 0.370 |
Why?
|
| Fast Foods | 2 | 2024 | 220 | 0.370 |
Why?
|
| Lignans | 2 | 2022 | 84 | 0.370 |
Why?
|
| Food, Fortified | 2 | 2015 | 189 | 0.370 |
Why?
|
| Fatty Acids | 2 | 2022 | 1812 | 0.360 |
Why?
|
| Secondary Prevention | 2 | 2015 | 1476 | 0.360 |
Why?
|
| Cathepsin B | 1 | 2010 | 80 | 0.350 |
Why?
|
| Pandemics | 11 | 2022 | 8745 | 0.350 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 729 | 0.350 |
Why?
|
| Waist-Hip Ratio | 5 | 2020 | 520 | 0.350 |
Why?
|
| Peptides | 3 | 2024 | 4353 | 0.340 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 1169 | 0.340 |
Why?
|
| Phenotype | 27 | 2023 | 16735 | 0.340 |
Why?
|
| Survival Analysis | 18 | 2022 | 10115 | 0.340 |
Why?
|
| Dementia | 1 | 2024 | 2741 | 0.340 |
Why?
|
| Adolescent | 38 | 2024 | 89247 | 0.340 |
Why?
|
| Skin Neoplasms | 4 | 2022 | 5864 | 0.340 |
Why?
|
| Bifidobacterium | 2 | 2021 | 99 | 0.330 |
Why?
|
| Health Occupations | 3 | 2021 | 225 | 0.330 |
Why?
|
| Diet Records | 2 | 2024 | 426 | 0.330 |
Why?
|
| Histamine H2 Antagonists | 3 | 2020 | 169 | 0.330 |
Why?
|
| Fusobacterium Infections | 2 | 2021 | 54 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2024 | 6546 | 0.320 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2022 | 475 | 0.320 |
Why?
|
| Minerals | 1 | 2010 | 282 | 0.320 |
Why?
|
| Hip Fractures | 2 | 2020 | 996 | 0.310 |
Why?
|
| Cause of Death | 9 | 2022 | 3721 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2015 | 10778 | 0.310 |
Why?
|
| Insulin | 9 | 2024 | 6610 | 0.310 |
Why?
|
| Ovarian Neoplasms | 6 | 2023 | 4919 | 0.310 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 957 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 10397 | 0.300 |
Why?
|
| Public Health | 4 | 2023 | 2680 | 0.300 |
Why?
|
| Metformin | 1 | 2016 | 909 | 0.300 |
Why?
|
| Adenosine Triphosphate | 2 | 2015 | 2003 | 0.300 |
Why?
|
| Specimen Handling | 3 | 2022 | 708 | 0.300 |
Why?
|
| Escherichia coli | 3 | 2024 | 4212 | 0.290 |
Why?
|
| Breast Neoplasms | 8 | 2024 | 21187 | 0.290 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 999 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2014 | 4528 | 0.290 |
Why?
|
| Epidemiologic Studies | 7 | 2022 | 677 | 0.290 |
Why?
|
| Patient Admission | 1 | 2015 | 1369 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2024 | 3814 | 0.280 |
Why?
|
| Eating | 4 | 2020 | 1542 | 0.280 |
Why?
|
| Laxatives | 2 | 2021 | 95 | 0.280 |
Why?
|
| Family | 1 | 2018 | 3208 | 0.280 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2020 | 542 | 0.280 |
Why?
|
| Genetic Heterogeneity | 2 | 2021 | 737 | 0.270 |
Why?
|
| Colitis, Lymphocytic | 2 | 2018 | 23 | 0.270 |
Why?
|
| Colitis, Collagenous | 2 | 2018 | 25 | 0.270 |
Why?
|
| Coronary Disease | 2 | 2021 | 5919 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 647 | 0.270 |
Why?
|
| DNA, Bacterial | 5 | 2018 | 1478 | 0.270 |
Why?
|
| Heterozygote | 2 | 2022 | 2798 | 0.270 |
Why?
|
| Survival Rate | 17 | 2020 | 12873 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 9442 | 0.260 |
Why?
|
| Mitochondria | 3 | 2020 | 3683 | 0.260 |
Why?
|
| Germ-Line Mutation | 6 | 2024 | 1887 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2012 | 3447 | 0.260 |
Why?
|
| Software | 1 | 2020 | 4480 | 0.260 |
Why?
|
| Treatment Outcome | 23 | 2023 | 65485 | 0.260 |
Why?
|
| Cholelithiasis | 2 | 2021 | 408 | 0.260 |
Why?
|
| Caffeine | 3 | 2020 | 703 | 0.250 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2019 | 558 | 0.250 |
Why?
|
| Food Handling | 2 | 2024 | 158 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 8664 | 0.250 |
Why?
|
| Diet, Vegetarian | 3 | 2022 | 181 | 0.250 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2021 | 708 | 0.240 |
Why?
|
| Comorbidity | 5 | 2021 | 10591 | 0.240 |
Why?
|
| Genetic Pleiotropy | 2 | 2018 | 181 | 0.240 |
Why?
|
| Internship and Residency | 2 | 2015 | 5956 | 0.240 |
Why?
|
| Citrus | 1 | 2024 | 49 | 0.240 |
Why?
|
| Bilophila | 1 | 2024 | 12 | 0.240 |
Why?
|
| 4-Butyrolactone | 2 | 2022 | 59 | 0.240 |
Why?
|
| Immunohistochemistry | 14 | 2021 | 11119 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 4 | 2019 | 415 | 0.230 |
Why?
|
| Brain Ischemia | 1 | 2017 | 3008 | 0.230 |
Why?
|
| Gastrointestinal Agents | 2 | 2021 | 510 | 0.230 |
Why?
|
| Alleles | 11 | 2021 | 6901 | 0.230 |
Why?
|
| Audiovisual Aids | 1 | 2005 | 99 | 0.230 |
Why?
|
| Models, Statistical | 6 | 2021 | 5107 | 0.220 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2006 | 660 | 0.220 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2020 | 304 | 0.220 |
Why?
|
| Forkhead Transcription Factors | 4 | 2020 | 1625 | 0.220 |
Why?
|
| Menopause | 6 | 2024 | 1656 | 0.220 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2024 | 1942 | 0.220 |
Why?
|
| Chromatography, Liquid | 2 | 2024 | 997 | 0.220 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1812 | 0.220 |
Why?
|
| Diarrhea | 2 | 2023 | 1319 | 0.220 |
Why?
|
| Methylamines | 2 | 2021 | 136 | 0.220 |
Why?
|
| Depression | 3 | 2024 | 8240 | 0.220 |
Why?
|
| Blood Glucose | 4 | 2022 | 6434 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2830 | 0.210 |
Why?
|
| Environmental Exposure | 1 | 2018 | 4538 | 0.210 |
Why?
|
| Epigenomics | 4 | 2017 | 961 | 0.210 |
Why?
|
| Colectomy | 3 | 2020 | 699 | 0.210 |
Why?
|
| Bacteroides fragilis | 1 | 2024 | 250 | 0.210 |
Why?
|
| Huntington Disease | 1 | 2010 | 1147 | 0.210 |
Why?
|
| Hemorrhage | 4 | 2024 | 3465 | 0.210 |
Why?
|
| Estrogens | 3 | 2022 | 1537 | 0.210 |
Why?
|
| Encephalitis | 1 | 2006 | 441 | 0.210 |
Why?
|
| Registries | 11 | 2021 | 8384 | 0.210 |
Why?
|
| Biology | 1 | 2005 | 292 | 0.210 |
Why?
|
| Estradiol | 5 | 2022 | 1952 | 0.210 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 3 | 2019 | 126 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 1737 | 0.200 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 1813 | 0.200 |
Why?
|
| Epigenesis, Genetic | 6 | 2021 | 3836 | 0.200 |
Why?
|
| Genes, ras | 3 | 2021 | 665 | 0.200 |
Why?
|
| Hypertension | 4 | 2022 | 8615 | 0.200 |
Why?
|
| Propionates | 1 | 2023 | 180 | 0.200 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 5892 | 0.200 |
Why?
|
| Confidence Intervals | 6 | 2021 | 2931 | 0.200 |
Why?
|
| Longitudinal Studies | 12 | 2024 | 14795 | 0.200 |
Why?
|
| Butyrates | 1 | 2023 | 167 | 0.200 |
Why?
|
| Drug Discovery | 2 | 2010 | 1068 | 0.200 |
Why?
|
| Principal Component Analysis | 4 | 2022 | 948 | 0.200 |
Why?
|
| Sleep | 2 | 2017 | 4820 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2004 | 269 | 0.190 |
Why?
|
| MicroRNAs | 5 | 2016 | 3811 | 0.190 |
Why?
|
| Meat Products | 2 | 2019 | 97 | 0.190 |
Why?
|
| Acetaminophen | 1 | 2006 | 556 | 0.190 |
Why?
|
| Salicylic Acid | 1 | 2021 | 62 | 0.190 |
Why?
|
| Animals | 31 | 2024 | 169408 | 0.190 |
Why?
|
| Ageusia | 1 | 2021 | 18 | 0.190 |
Why?
|
| China | 4 | 2024 | 2395 | 0.190 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 400 | 0.190 |
Why?
|
| Keloid | 1 | 2022 | 55 | 0.190 |
Why?
|
| Moyamoya Disease | 1 | 2005 | 274 | 0.190 |
Why?
|
| Microglia | 3 | 2007 | 1376 | 0.190 |
Why?
|
| Biliary Tract | 1 | 2022 | 135 | 0.190 |
Why?
|
| Neuropsychological Tests | 3 | 2022 | 7148 | 0.190 |
Why?
|
| Fusobacterium | 1 | 2021 | 56 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 11886 | 0.190 |
Why?
|
| Monosaccharides | 1 | 2021 | 64 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2024 | 1197 | 0.180 |
Why?
|
| Cross-Sectional Studies | 13 | 2023 | 26384 | 0.180 |
Why?
|
| Lymphocytes | 3 | 2020 | 2614 | 0.180 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2024 | 301 | 0.180 |
Why?
|
| Chronic Disease | 6 | 2023 | 9384 | 0.180 |
Why?
|
| Phagocytosis | 1 | 2006 | 1530 | 0.180 |
Why?
|
| Prescription Drugs | 2 | 2020 | 635 | 0.180 |
Why?
|
| Psychomotor Agitation | 1 | 2023 | 307 | 0.180 |
Why?
|
| Breast Feeding | 2 | 2023 | 1364 | 0.180 |
Why?
|
| Somatotypes | 1 | 2020 | 40 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2024 | 3554 | 0.180 |
Why?
|
| Cadherins | 2 | 2016 | 906 | 0.180 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 224 | 0.180 |
Why?
|
| Databases, Genetic | 6 | 2022 | 1758 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2016 | 4755 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 2 | 2024 | 2487 | 0.180 |
Why?
|
| Community Health Centers | 1 | 2024 | 469 | 0.180 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 517 | 0.180 |
Why?
|
| Ferritins | 3 | 2023 | 600 | 0.180 |
Why?
|
| Prevalence | 9 | 2024 | 15875 | 0.180 |
Why?
|
| Up-Regulation | 7 | 2019 | 4148 | 0.180 |
Why?
|
| Adenoma, Villous | 1 | 2020 | 13 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 7460 | 0.170 |
Why?
|
| Stroke | 2 | 2024 | 9756 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 3 | 2024 | 3629 | 0.170 |
Why?
|
| Nuts | 2 | 2019 | 264 | 0.170 |
Why?
|
| Computational Biology | 5 | 2020 | 3562 | 0.170 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 15471 | 0.170 |
Why?
|
| Models, Biological | 4 | 2021 | 9499 | 0.170 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2023 | 565 | 0.170 |
Why?
|
| Hydrogen Sulfide | 1 | 2021 | 147 | 0.170 |
Why?
|
| Gastrointestinal Tract | 3 | 2015 | 839 | 0.170 |
Why?
|
| Prostatic Neoplasms | 5 | 2024 | 11229 | 0.170 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2019 | 32 | 0.170 |
Why?
|
| Research Design | 8 | 2019 | 6213 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 878 | 0.160 |
Why?
|
| Age Distribution | 5 | 2021 | 2875 | 0.160 |
Why?
|
| RNA, Messenger | 11 | 2023 | 12809 | 0.160 |
Why?
|
| End Stage Liver Disease | 1 | 2024 | 370 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 1033 | 0.160 |
Why?
|
| Models, Genetic | 3 | 2020 | 3446 | 0.160 |
Why?
|
| Gastrointestinal Motility | 1 | 2021 | 236 | 0.160 |
Why?
|
| Gastric Mucosa | 1 | 2022 | 602 | 0.160 |
Why?
|
| Plants, Medicinal | 1 | 2020 | 167 | 0.160 |
Why?
|
| DNA, Neoplasm | 4 | 2013 | 1748 | 0.160 |
Why?
|
| Vaccination | 2 | 2022 | 3436 | 0.160 |
Why?
|
| Fatty Acid Desaturases | 1 | 2019 | 102 | 0.160 |
Why?
|
| Caloric Restriction | 1 | 2021 | 301 | 0.160 |
Why?
|
| Melanoma | 3 | 2022 | 5709 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 3709 | 0.160 |
Why?
|
| Granulocytes | 1 | 2021 | 551 | 0.160 |
Why?
|
| Bifidobacteriales Infections | 1 | 2018 | 10 | 0.160 |
Why?
|
| Estrone | 1 | 2020 | 234 | 0.160 |
Why?
|
| Paraffin Embedding | 1 | 2020 | 306 | 0.160 |
Why?
|
| Tissue Fixation | 1 | 2020 | 245 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 2004 | 538 | 0.160 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2020 | 190 | 0.160 |
Why?
|
| Microsatellite Repeats | 3 | 2015 | 785 | 0.160 |
Why?
|
| Disease Susceptibility | 3 | 2021 | 1794 | 0.160 |
Why?
|
| Phylogeny | 2 | 2024 | 2843 | 0.160 |
Why?
|
| Fishes | 3 | 2019 | 606 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2005 | 1363 | 0.160 |
Why?
|
| Haplotypes | 3 | 2016 | 2725 | 0.150 |
Why?
|
| Bilirubin | 1 | 2020 | 438 | 0.150 |
Why?
|
| Genetic Association Studies | 7 | 2018 | 2747 | 0.150 |
Why?
|
| Natural Killer T-Cells | 1 | 2021 | 318 | 0.150 |
Why?
|
| Formaldehyde | 1 | 2020 | 361 | 0.150 |
Why?
|
| Arachidonic Acid | 1 | 2020 | 429 | 0.150 |
Why?
|
| Glucosinolates | 1 | 2018 | 11 | 0.150 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 524 | 0.150 |
Why?
|
| Germany | 6 | 2018 | 883 | 0.150 |
Why?
|
| Nutritional Status | 2 | 2018 | 1627 | 0.150 |
Why?
|
| Micronutrients | 1 | 2021 | 390 | 0.150 |
Why?
|
| Fatty Acids, Omega-6 | 2 | 2022 | 225 | 0.150 |
Why?
|
| Polyps | 1 | 2020 | 200 | 0.150 |
Why?
|
| Isothiocyanates | 1 | 2018 | 48 | 0.150 |
Why?
|
| Gallbladder Neoplasms | 1 | 2019 | 190 | 0.150 |
Why?
|
| Signal Transduction | 8 | 2024 | 23652 | 0.150 |
Why?
|
| Beverages | 2 | 2022 | 819 | 0.150 |
Why?
|
| Lymphocyte Count | 5 | 2020 | 793 | 0.150 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2021 | 263 | 0.150 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2018 | 81 | 0.150 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 683 | 0.150 |
Why?
|
| Massachusetts | 4 | 2021 | 8888 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 1494 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2024 | 2848 | 0.150 |
Why?
|
| Lipid Metabolism | 2 | 2024 | 1904 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2018 | 193 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
| Obesity, Abdominal | 2 | 2018 | 375 | 0.140 |
Why?
|
| Drug Eruptions | 1 | 2020 | 335 | 0.140 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2019 | 271 | 0.140 |
Why?
|
| Disease Progression | 9 | 2019 | 13677 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 410 | 0.140 |
Why?
|
| Poultry Products | 1 | 2017 | 10 | 0.140 |
Why?
|
| Europe | 5 | 2024 | 3441 | 0.140 |
Why?
|
| Cough | 1 | 2021 | 598 | 0.140 |
Why?
|
| Blood Pressure | 1 | 2013 | 8541 | 0.140 |
Why?
|
| Cytokines | 3 | 2024 | 7453 | 0.140 |
Why?
|
| Sex Distribution | 4 | 2015 | 2280 | 0.140 |
Why?
|
| Fish Products | 1 | 2017 | 31 | 0.140 |
Why?
|
| Smoke | 1 | 2019 | 236 | 0.140 |
Why?
|
| Biological Availability | 1 | 2018 | 392 | 0.140 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2019 | 268 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2024 | 1203 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 5443 | 0.140 |
Why?
|
| Aptamers, Nucleotide | 1 | 2018 | 163 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 15955 | 0.140 |
Why?
|
| Estrogen Receptor beta | 2 | 2020 | 171 | 0.140 |
Why?
|
| Cultural Diversity | 1 | 2020 | 373 | 0.140 |
Why?
|
| Gene Frequency | 7 | 2019 | 3625 | 0.140 |
Why?
|
| Inheritance Patterns | 1 | 2019 | 344 | 0.140 |
Why?
|
| Triglycerides | 1 | 2024 | 2464 | 0.130 |
Why?
|
| Iron | 1 | 2005 | 1813 | 0.130 |
Why?
|
| Mitoxantrone | 1 | 2016 | 148 | 0.130 |
Why?
|
| Chondroitin | 1 | 2016 | 64 | 0.130 |
Why?
|
| Dyspnea | 2 | 2021 | 1352 | 0.130 |
Why?
|
| Beer | 1 | 2016 | 135 | 0.130 |
Why?
|
| Plasma | 2 | 2019 | 585 | 0.130 |
Why?
|
| Pancreatic Pseudocyst | 1 | 1996 | 112 | 0.130 |
Why?
|
| Glucosamine | 1 | 2016 | 128 | 0.130 |
Why?
|
| Plasminogen | 1 | 2016 | 144 | 0.130 |
Why?
|
| Hormones | 1 | 2020 | 871 | 0.130 |
Why?
|
| Drug Utilization | 3 | 2019 | 1191 | 0.130 |
Why?
|
| Wine | 1 | 2016 | 172 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 3253 | 0.130 |
Why?
|
| Polymorphism, Genetic | 5 | 2011 | 4251 | 0.130 |
Why?
|
| Selection Bias | 1 | 2017 | 360 | 0.130 |
Why?
|
| Plants, Edible | 1 | 2015 | 29 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 744 | 0.130 |
Why?
|
| Calcium | 3 | 2019 | 5792 | 0.130 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2016 | 131 | 0.130 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2017 | 320 | 0.130 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 857 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 560 | 0.130 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2013 | 153 | 0.130 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2013 | 558 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 413 | 0.130 |
Why?
|
| Bismuth | 1 | 2015 | 29 | 0.120 |
Why?
|
| Cyclin D1 | 2 | 2008 | 453 | 0.120 |
Why?
|
| Menarche | 1 | 2018 | 538 | 0.120 |
Why?
|
| Job Description | 1 | 2015 | 61 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 370 | 0.120 |
Why?
|
| Organoids | 1 | 2021 | 745 | 0.120 |
Why?
|
| Tetracycline | 1 | 2015 | 216 | 0.120 |
Why?
|
| Allied Health Personnel | 1 | 2016 | 156 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2024 | 1346 | 0.120 |
Why?
|
| Androgens | 1 | 2022 | 1285 | 0.120 |
Why?
|
| Aging | 5 | 2021 | 8765 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 286 | 0.120 |
Why?
|
| Coffea | 1 | 2014 | 22 | 0.120 |
Why?
|
| Rosacea | 1 | 2015 | 60 | 0.120 |
Why?
|
| Salicylates | 1 | 2015 | 128 | 0.120 |
Why?
|
| Cholesterol | 2 | 2022 | 2913 | 0.120 |
Why?
|
| Folic Acid Deficiency | 1 | 2015 | 117 | 0.120 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 325 | 0.120 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 13593 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 3626 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 640 | 0.120 |
Why?
|
| Tumor Escape | 1 | 2017 | 372 | 0.120 |
Why?
|
| Progesterone | 1 | 2019 | 752 | 0.120 |
Why?
|
| Ultraviolet Rays | 2 | 2021 | 1104 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 9549 | 0.120 |
Why?
|
| Anthropometry | 1 | 2019 | 1343 | 0.120 |
Why?
|
| Child, Preschool | 7 | 2022 | 42684 | 0.120 |
Why?
|
| Calcium Signaling | 1 | 2019 | 738 | 0.110 |
Why?
|
| Plant Proteins | 1 | 2016 | 376 | 0.110 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 119 | 0.110 |
Why?
|
| Budesonide | 1 | 2015 | 162 | 0.110 |
Why?
|
| Body Fat Distribution | 1 | 2015 | 246 | 0.110 |
Why?
|
| Preventive Medicine | 1 | 2015 | 246 | 0.110 |
Why?
|
| Endometriosis | 1 | 2022 | 874 | 0.110 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 121 | 0.110 |
Why?
|
| Hydrochlorothiazide | 1 | 2014 | 95 | 0.110 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2017 | 792 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2015 | 224 | 0.110 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3608 | 0.110 |
Why?
|
| Indiana | 1 | 2013 | 93 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2020 | 3116 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2020 | 10486 | 0.110 |
Why?
|
| alpha-Mannosidase | 1 | 2013 | 19 | 0.110 |
Why?
|
| Prostaglandin Antagonists | 1 | 2013 | 28 | 0.110 |
Why?
|
| Fever | 1 | 2021 | 1620 | 0.110 |
Why?
|
| Anemia | 1 | 2023 | 1516 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2012 | 379 | 0.110 |
Why?
|
| Retrospective Studies | 14 | 2021 | 81892 | 0.110 |
Why?
|
| Recurrence | 2 | 2020 | 8512 | 0.110 |
Why?
|
| International Cooperation | 1 | 2020 | 1436 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2014 | 4593 | 0.110 |
Why?
|
| Protein Interaction Mapping | 1 | 2017 | 621 | 0.110 |
Why?
|
| Infusions, Subcutaneous | 1 | 2013 | 43 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 1422 | 0.110 |
Why?
|
| SOXE Transcription Factors | 1 | 2013 | 73 | 0.110 |
Why?
|
| Ankyrin Repeat | 1 | 2013 | 19 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 103 | 0.110 |
Why?
|
| Receptors, CXCR5 | 1 | 2013 | 88 | 0.110 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2010 | 822 | 0.110 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2023 | 888 | 0.110 |
Why?
|
| Kallikreins | 1 | 2014 | 219 | 0.100 |
Why?
|
| Research Report | 1 | 2016 | 369 | 0.100 |
Why?
|
| Calcifediol | 1 | 2013 | 160 | 0.100 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 7860 | 0.100 |
Why?
|
| Boston | 3 | 2017 | 9375 | 0.100 |
Why?
|
| Vitamin B Complex | 1 | 2015 | 299 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 493 | 0.100 |
Why?
|
| Clinical Protocols | 2 | 2017 | 1445 | 0.100 |
Why?
|
| Receptors, Interleukin | 1 | 2014 | 243 | 0.100 |
Why?
|
| Cyclin D2 | 1 | 2012 | 98 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 592 | 0.100 |
Why?
|
| Body Height | 2 | 2018 | 1568 | 0.100 |
Why?
|
| Immunologic Factors | 2 | 2015 | 1597 | 0.100 |
Why?
|
| JC Virus | 1 | 2013 | 87 | 0.100 |
Why?
|
| Walking | 1 | 2020 | 1201 | 0.100 |
Why?
|
| Biopsy | 4 | 2020 | 6805 | 0.100 |
Why?
|
| Databases, Factual | 7 | 2019 | 8095 | 0.100 |
Why?
|
| Choline | 2 | 2021 | 522 | 0.100 |
Why?
|
| Television | 1 | 2015 | 410 | 0.100 |
Why?
|
| Forecasting | 1 | 2022 | 2946 | 0.100 |
Why?
|
| Proteins | 4 | 2023 | 6011 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 2183 | 0.100 |
Why?
|
| Cisplatin | 1 | 2018 | 1661 | 0.100 |
Why?
|
| Codon | 1 | 2014 | 599 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 1190 | 0.100 |
Why?
|
| Wnt Proteins | 2 | 2013 | 725 | 0.100 |
Why?
|
| Energy Intake | 2 | 2017 | 2146 | 0.100 |
Why?
|
| Biostatistics | 1 | 2014 | 165 | 0.100 |
Why?
|
| Serum | 1 | 2013 | 207 | 0.100 |
Why?
|
| Weight Loss | 1 | 2024 | 2720 | 0.100 |
Why?
|
| Tablets | 2 | 2022 | 149 | 0.100 |
Why?
|
| Disability Evaluation | 2 | 2016 | 1839 | 0.100 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2014 | 251 | 0.100 |
Why?
|
| Health Status | 3 | 2023 | 4095 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2015 | 499 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 3 | 2015 | 1469 | 0.100 |
Why?
|
| Cooking | 1 | 2014 | 314 | 0.100 |
Why?
|
| Autophagy | 1 | 2020 | 1351 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 515 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2014 | 361 | 0.100 |
Why?
|
| Nutritive Value | 1 | 2015 | 351 | 0.100 |
Why?
|
| Receptors, Ghrelin | 1 | 2011 | 20 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 570 | 0.100 |
Why?
|
| Quality Control | 1 | 2014 | 836 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2012 | 2941 | 0.100 |
Why?
|
| Government Programs | 1 | 2014 | 278 | 0.100 |
Why?
|
| Organometallic Compounds | 1 | 2015 | 648 | 0.090 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 385 | 0.090 |
Why?
|
| Monocytes | 1 | 2021 | 2603 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 6232 | 0.090 |
Why?
|
| Neuromyelitis Optica | 1 | 2015 | 266 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 1855 | 0.090 |
Why?
|
| Dietary Proteins | 1 | 2016 | 960 | 0.090 |
Why?
|
| Hypercalcemia | 1 | 2014 | 424 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2020 | 2576 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2020 | 3671 | 0.090 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 3438 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 14751 | 0.090 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 3047 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 859 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2020 | 2421 | 0.090 |
Why?
|
| Antioxidants | 2 | 2019 | 1673 | 0.090 |
Why?
|
| Polyomavirus Infections | 1 | 2013 | 192 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1039 | 0.090 |
Why?
|
| Smoking Cessation | 4 | 2018 | 2084 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2015 | 4940 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2016 | 584 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 353 | 0.090 |
Why?
|
| Drainage | 1 | 1996 | 1184 | 0.090 |
Why?
|
| Helicobacter pylori | 1 | 2014 | 380 | 0.090 |
Why?
|
| Arthroplasty, Replacement | 1 | 2014 | 311 | 0.090 |
Why?
|
| Israel | 2 | 2024 | 726 | 0.090 |
Why?
|
| Demyelinating Diseases | 1 | 2013 | 358 | 0.090 |
Why?
|
| Linear Models | 2 | 2017 | 5890 | 0.090 |
Why?
|
| Internet | 2 | 2020 | 3112 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 733 | 0.090 |
Why?
|
| Epidemiology | 1 | 2013 | 278 | 0.090 |
Why?
|
| Disease | 1 | 2015 | 673 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2019 | 2813 | 0.090 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2010 | 56 | 0.090 |
Why?
|
| Vitamin B 12 | 3 | 2021 | 528 | 0.090 |
Why?
|
| Blood Donors | 1 | 2012 | 344 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2015 | 1336 | 0.090 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 4207 | 0.090 |
Why?
|
| DNA Repair | 1 | 2019 | 2054 | 0.080 |
Why?
|
| Nephrolithiasis | 1 | 2011 | 117 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 1321 | 0.080 |
Why?
|
| Geography | 1 | 2012 | 654 | 0.080 |
Why?
|
| Reproducibility of Results | 8 | 2022 | 20244 | 0.080 |
Why?
|
| HLA-DR Antigens | 2 | 2021 | 609 | 0.080 |
Why?
|
| Arthritis, Psoriatic | 1 | 2012 | 219 | 0.080 |
Why?
|
| Lymphocyte Activation | 3 | 2016 | 5505 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2001 | 957 | 0.080 |
Why?
|
| Ghrelin | 1 | 2011 | 251 | 0.080 |
Why?
|
| Colitis | 1 | 2018 | 1244 | 0.080 |
Why?
|
| Intellectual Property | 1 | 2009 | 32 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2020 | 2701 | 0.080 |
Why?
|
| Markov Chains | 1 | 2013 | 979 | 0.080 |
Why?
|
| Keratins | 2 | 2001 | 502 | 0.080 |
Why?
|
| Causality | 3 | 2021 | 1255 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2022 | 2819 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 5801 | 0.080 |
Why?
|
| Stathmin | 1 | 2009 | 70 | 0.080 |
Why?
|
| INDEL Mutation | 2 | 2020 | 267 | 0.080 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 417 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 1182 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2005 | 7885 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2019 | 640 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 1143 | 0.080 |
Why?
|
| Probability | 2 | 2017 | 2483 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 1895 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2020 | 3580 | 0.080 |
Why?
|
| Integrin alpha4 | 1 | 2008 | 88 | 0.080 |
Why?
|
| Osteopontin | 2 | 2008 | 311 | 0.080 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 6320 | 0.080 |
Why?
|
| Career Choice | 1 | 2015 | 769 | 0.080 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 4926 | 0.080 |
Why?
|
| Somatomedins | 1 | 2008 | 179 | 0.080 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2009 | 123 | 0.080 |
Why?
|
| Rats, Inbred Lew | 2 | 2007 | 1163 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2020 | 3335 | 0.070 |
Why?
|
| Genetic Markers | 4 | 2021 | 2604 | 0.070 |
Why?
|
| Body Weight | 3 | 2024 | 4628 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2008 | 138 | 0.070 |
Why?
|
| Immunoglobulin M | 2 | 2023 | 1528 | 0.070 |
Why?
|
| Mental Health | 1 | 2022 | 3275 | 0.070 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2014 | 607 | 0.070 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 551 | 0.070 |
Why?
|
| Memory | 1 | 2017 | 2210 | 0.070 |
Why?
|
| Hyperplasia | 3 | 2020 | 1154 | 0.070 |
Why?
|
| Flavanones | 2 | 2019 | 75 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 875 | 0.070 |
Why?
|
| Betaine | 1 | 2007 | 90 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 3200 | 0.070 |
Why?
|
| Genome, Human | 1 | 2020 | 4456 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2022 | 4123 | 0.070 |
Why?
|
| Shoulder Joint | 1 | 2014 | 747 | 0.070 |
Why?
|
| Thrombosis | 2 | 2016 | 2956 | 0.070 |
Why?
|
| Benchmarking | 1 | 2013 | 1058 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2021 | 3982 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 6085 | 0.070 |
Why?
|
| Attention | 1 | 2017 | 2425 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 1248 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2009 | 326 | 0.070 |
Why?
|
| Fibrinolytic Agents | 2 | 2011 | 2080 | 0.070 |
Why?
|
| Reference Values | 2 | 2016 | 4941 | 0.070 |
Why?
|
| Gelatinases | 1 | 2006 | 93 | 0.070 |
Why?
|
| Urban Population | 1 | 2015 | 2045 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2665 | 0.070 |
Why?
|
| Schools | 1 | 2015 | 1498 | 0.070 |
Why?
|
| Joint Instability | 1 | 2014 | 803 | 0.070 |
Why?
|
| Apolipoproteins E | 1 | 2012 | 1461 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 2475 | 0.070 |
Why?
|
| Oxidative Stress | 4 | 2020 | 3138 | 0.070 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 3216 | 0.070 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2007 | 71 | 0.070 |
Why?
|
| Chromosome Mapping | 3 | 2024 | 4624 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8559 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 6031 | 0.070 |
Why?
|
| Nutrition Policy | 1 | 2010 | 467 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3621 | 0.070 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 1695 | 0.070 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 662 | 0.070 |
Why?
|
| Osteoarthritis | 1 | 2014 | 1070 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 627 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 214 | 0.060 |
Why?
|
| Natural Language Processing | 1 | 2015 | 1203 | 0.060 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2008 | 290 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 2820 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 4300 | 0.060 |
Why?
|
| Lysine | 1 | 2010 | 1000 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2023 | 640 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 1060 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2013 | 1813 | 0.060 |
Why?
|
| Republic of Korea | 2 | 2019 | 592 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2013 | 4042 | 0.060 |
Why?
|
| Epoxide Hydrolases | 1 | 2005 | 122 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 2574 | 0.060 |
Why?
|
| Birth Weight | 1 | 2013 | 2108 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2006 | 642 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2016 | 2911 | 0.060 |
Why?
|
| Epidemiologic Factors | 1 | 2024 | 36 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 1674 | 0.060 |
Why?
|
| Education, Graduate | 1 | 2005 | 75 | 0.060 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2024 | 44 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 2931 | 0.060 |
Why?
|
| Monoamine Oxidase | 1 | 2024 | 180 | 0.060 |
Why?
|
| Infant | 3 | 2023 | 36541 | 0.060 |
Why?
|
| Child | 11 | 2024 | 80969 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1705 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2016 | 3473 | 0.060 |
Why?
|
| Transferrin | 1 | 2005 | 284 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 606 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2010 | 1309 | 0.060 |
Why?
|
| Rural Population | 1 | 2015 | 2322 | 0.060 |
Why?
|
| Gerbillinae | 1 | 2023 | 87 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2005 | 176 | 0.060 |
Why?
|
| Vitamin B 6 | 2 | 2015 | 237 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 300 | 0.050 |
Why?
|
| Multifactorial Inheritance | 2 | 2023 | 1423 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2905 | 0.050 |
Why?
|
| Physical Exertion | 1 | 2006 | 668 | 0.050 |
Why?
|
| Occult Blood | 1 | 2024 | 199 | 0.050 |
Why?
|
| S-Adenosylmethionine | 1 | 2024 | 219 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2019 | 1998 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2013 | 2121 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 440 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 3782 | 0.050 |
Why?
|
| Kynurenine | 1 | 2023 | 142 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 2960 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2001 | 338 | 0.050 |
Why?
|
| Japan | 2 | 2019 | 1418 | 0.050 |
Why?
|
| Dental Caries Susceptibility | 1 | 2022 | 28 | 0.050 |
Why?
|
| Drug Industry | 1 | 2009 | 793 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2012 | 1606 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 9264 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2002 | 77 | 0.050 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2005 | 414 | 0.050 |
Why?
|
| Bronchial Neoplasms | 1 | 2003 | 111 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 100 | 0.050 |
Why?
|
| Mesalamine | 1 | 2023 | 134 | 0.050 |
Why?
|
| Chemokines | 1 | 2006 | 963 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 930 | 0.050 |
Why?
|
| Astrocytes | 2 | 2007 | 1349 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 5544 | 0.050 |
Why?
|
| Nutrition Surveys | 2 | 2022 | 1738 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2022 | 199 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2006 | 905 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 1515 | 0.050 |
Why?
|
| Electron Transport Complex IV | 1 | 2022 | 192 | 0.050 |
Why?
|
| Furosemide | 1 | 2022 | 174 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2122 | 0.050 |
Why?
|
| Tryptophan | 1 | 2023 | 482 | 0.050 |
Why?
|
| Hospitalization | 3 | 2020 | 10845 | 0.050 |
Why?
|
| Colon, Descending | 1 | 2021 | 6 | 0.050 |
Why?
|
| Curriculum | 1 | 2015 | 3782 | 0.050 |
Why?
|
| Colon, Ascending | 1 | 2021 | 14 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2015 | 3313 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 3048 | 0.050 |
Why?
|
| Nutrition Assessment | 1 | 2024 | 740 | 0.050 |
Why?
|
| Prebiotics | 1 | 2021 | 41 | 0.050 |
Why?
|
| Reminder Systems | 1 | 2024 | 388 | 0.050 |
Why?
|
| Immune System | 1 | 2006 | 800 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2024 | 11521 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 1305 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2022 | 408 | 0.050 |
Why?
|
| Colon, Transverse | 1 | 2021 | 25 | 0.050 |
Why?
|
| Prevotella | 1 | 2021 | 81 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 11934 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 36861 | 0.050 |
Why?
|
| Intention | 1 | 2024 | 348 | 0.050 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 8055 | 0.050 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 1094 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 1437 | 0.040 |
Why?
|
| Hematoxylin | 1 | 2020 | 61 | 0.040 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2020 | 70 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2021 | 124 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 2 | 2009 | 358 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1866 | 0.040 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cecum | 1 | 2021 | 231 | 0.040 |
Why?
|
| Proctoscopy | 1 | 2020 | 40 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 4053 | 0.040 |
Why?
|
| Fructose | 1 | 2022 | 284 | 0.040 |
Why?
|
| Cell Movement | 2 | 2016 | 5216 | 0.040 |
Why?
|
| Germ Cells | 1 | 2024 | 644 | 0.040 |
Why?
|
| Dietary Carbohydrates | 2 | 2018 | 896 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2020 | 2357 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2012 | 317 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2000 | 229 | 0.040 |
Why?
|
| Germinoma | 1 | 2000 | 132 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2020 | 50 | 0.040 |
Why?
|
| Poultry | 1 | 2019 | 79 | 0.040 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2019 | 50 | 0.040 |
Why?
|
| Survivors | 1 | 2010 | 2383 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 165 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 446 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2017 | 11684 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 9081 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 2211 | 0.040 |
Why?
|
| Mammals | 1 | 2005 | 1136 | 0.040 |
Why?
|
| Yogurt | 1 | 2019 | 71 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2021 | 409 | 0.040 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2019 | 121 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 2019 | 85 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 691 | 0.040 |
Why?
|
| Lymphoid Tissue | 2 | 2014 | 446 | 0.040 |
Why?
|
| Ampulla of Vater | 1 | 2019 | 150 | 0.040 |
Why?
|
| Mortality | 2 | 2021 | 2915 | 0.040 |
Why?
|
| Analgesics | 1 | 2006 | 1072 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2019 | 86 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2014 | 1328 | 0.040 |
Why?
|
| Bile Ducts | 1 | 2020 | 288 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 2222 | 0.040 |
Why?
|
| DNA | 1 | 2012 | 7214 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2019 | 210 | 0.040 |
Why?
|
| Trans Fatty Acids | 1 | 2019 | 155 | 0.040 |
Why?
|
| Rectus Abdominis | 1 | 2019 | 102 | 0.040 |
Why?
|
| Methylation | 1 | 2021 | 1078 | 0.040 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 223 | 0.040 |
Why?
|
| Oxidants | 1 | 2019 | 168 | 0.040 |
Why?
|
| Career Mobility | 1 | 2020 | 262 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 756 | 0.040 |
Why?
|
| Selenium | 1 | 2021 | 418 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2024 | 2663 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 800 | 0.040 |
Why?
|
| Pregnancy | 3 | 2024 | 30175 | 0.040 |
Why?
|
| Ketones | 1 | 2019 | 183 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 1999 | 9213 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2021 | 4356 | 0.040 |
Why?
|
| Pedigree | 2 | 2016 | 4545 | 0.040 |
Why?
|
| Financial Management | 1 | 2019 | 161 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 556 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2019 | 414 | 0.040 |
Why?
|
| Viremia | 1 | 2020 | 725 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2019 | 346 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 1999 | 344 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 2020 | 2660 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2016 | 12174 | 0.040 |
Why?
|
| Cell Count | 2 | 2015 | 1833 | 0.040 |
Why?
|
| Glycemic Index | 1 | 2019 | 400 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2020 | 19023 | 0.040 |
Why?
|
| Probiotics | 1 | 2021 | 382 | 0.030 |
Why?
|
| Mice | 7 | 2024 | 82074 | 0.030 |
Why?
|
| Headache | 1 | 2005 | 1263 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2023 | 1531 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2024 | 2204 | 0.030 |
Why?
|
| Women's Health | 2 | 2019 | 2081 | 0.030 |
Why?
|
| ROC Curve | 2 | 2018 | 3629 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 1999 | 15889 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 1243 | 0.030 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2016 | 34 | 0.030 |
Why?
|
| Platelet Count | 1 | 2019 | 787 | 0.030 |
Why?
|
| HIV-1 | 1 | 2014 | 6963 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2021 | 1195 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 2916 | 0.030 |
Why?
|
| Siblings | 1 | 2020 | 829 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2023 | 1658 | 0.030 |
Why?
|
| Independent Living | 1 | 2020 | 584 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1608 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 581 | 0.030 |
Why?
|
| Social Justice | 1 | 2020 | 486 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2020 | 1081 | 0.030 |
Why?
|
| Ribotyping | 1 | 2015 | 35 | 0.030 |
Why?
|
| Flavones | 1 | 2015 | 66 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 1064 | 0.030 |
Why?
|
| Child Abuse | 1 | 2024 | 1097 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2016 | 365 | 0.030 |
Why?
|
| Anthocyanins | 1 | 2015 | 80 | 0.030 |
Why?
|
| Heparin | 1 | 2003 | 1636 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3724 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 2094 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 1120 | 0.030 |
Why?
|
| Flavonols | 1 | 2015 | 85 | 0.030 |
Why?
|
| Cattle | 1 | 2021 | 3820 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2017 | 320 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 405 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 378 | 0.030 |
Why?
|
| Pancreas | 1 | 2022 | 1700 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2024 | 1891 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1159 | 0.030 |
Why?
|
| Physicians | 2 | 2011 | 4607 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.030 |
Why?
|
| Tumor Necrosis Factors | 1 | 2015 | 109 | 0.030 |
Why?
|
| Riboflavin | 1 | 2015 | 107 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 300 | 0.030 |
Why?
|
| Oral Health | 1 | 2020 | 493 | 0.030 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 9618 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2014 | 68 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2016 | 4032 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2020 | 1073 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2020 | 866 | 0.030 |
Why?
|
| Communication | 1 | 2009 | 3908 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 1216 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 831 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 789 | 0.030 |
Why?
|
| Florida | 1 | 2015 | 430 | 0.030 |
Why?
|
| Algorithms | 1 | 2015 | 14199 | 0.030 |
Why?
|
| Chest Pain | 1 | 2021 | 1101 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2000 | 911 | 0.030 |
Why?
|
| Drinking | 1 | 2015 | 196 | 0.030 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 1994 | 140 | 0.030 |
Why?
|
| DNA Damage | 1 | 2024 | 2472 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2015 | 6346 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2022 | 2492 | 0.030 |
Why?
|
| Joint Capsule | 1 | 2014 | 68 | 0.030 |
Why?
|
| Nicotine | 1 | 2019 | 681 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1994 | 330 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2014 | 862 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2021 | 2635 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 2460 | 0.030 |
Why?
|
| Fibrosis | 1 | 2021 | 2081 | 0.030 |
Why?
|
| Internationality | 1 | 2019 | 1008 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2015 | 310 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 144 | 0.030 |
Why?
|
| Gastrostomy | 1 | 1996 | 325 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2015 | 361 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 2016 | 428 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2015 | 432 | 0.030 |
Why?
|
| Rats | 2 | 2007 | 23847 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2020 | 1320 | 0.030 |
Why?
|
| Educational Status | 1 | 2021 | 2515 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2041 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2016 | 659 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 123 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2019 | 1575 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2015 | 475 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 2026 | 0.030 |
Why?
|
| Leucovorin | 1 | 2014 | 643 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1407 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2013 | 26394 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2024 | 7609 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2018 | 6289 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 1893 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 2014 | 5905 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2014 | 393 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 812 | 0.020 |
Why?
|
| Men | 1 | 2012 | 64 | 0.020 |
Why?
|
| Seizures | 1 | 2005 | 3000 | 0.020 |
Why?
|
| Methionine | 1 | 2014 | 573 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2020 | 2871 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 2749 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2016 | 2179 | 0.020 |
Why?
|
| Sigmoid Neoplasms | 1 | 2012 | 53 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 4413 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 1104 | 0.020 |
Why?
|
| Fasting | 1 | 2018 | 1610 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 325 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2252 | 0.020 |
Why?
|
| Environment | 1 | 2018 | 1125 | 0.020 |
Why?
|
| Mouth | 1 | 2014 | 383 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2013 | 411 | 0.020 |
Why?
|
| Laminin | 1 | 2012 | 406 | 0.020 |
Why?
|
| Telomerase | 1 | 2016 | 753 | 0.020 |
Why?
|
| Endoscopy | 1 | 2021 | 1862 | 0.020 |
Why?
|
| Creatine | 1 | 2013 | 427 | 0.020 |
Why?
|
| Viral Load | 1 | 2020 | 3398 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2023 | 3967 | 0.020 |
Why?
|
| Quality of Life | 2 | 2023 | 13510 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 609 | 0.020 |
Why?
|
| Camptothecin | 1 | 2014 | 600 | 0.020 |
Why?
|
| Pain | 1 | 2006 | 5100 | 0.020 |
Why?
|
| Emotions | 1 | 2023 | 2768 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2013 | 577 | 0.020 |
Why?
|
| Premenopause | 1 | 2015 | 1039 | 0.020 |
Why?
|
| Diuretics | 1 | 2014 | 614 | 0.020 |
Why?
|
| Macrophages | 2 | 2021 | 5800 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 4568 | 0.020 |
Why?
|
| Women | 1 | 2012 | 225 | 0.020 |
Why?
|
| Apoptosis | 1 | 2006 | 9528 | 0.020 |
Why?
|
| Interdisciplinary Studies | 1 | 2010 | 86 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2017 | 3631 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4352 | 0.020 |
Why?
|
| Alcoholism | 1 | 2021 | 1981 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2010 | 48 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 400 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 472 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 1356 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 2001 | 777 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2017 | 1802 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 1364 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 1151 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 771 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2015 | 959 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 18366 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 848 | 0.020 |
Why?
|
| Saliva | 1 | 2014 | 855 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2606 | 0.020 |
Why?
|
| Kinetics | 1 | 2017 | 6334 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1752 | 0.020 |
Why?
|
| RNA Stability | 1 | 2011 | 321 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 6131 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 3421 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3903 | 0.020 |
Why?
|
| Morbidity | 1 | 2014 | 1757 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 1418 | 0.020 |
Why?
|
| Brain | 2 | 2023 | 27476 | 0.020 |
Why?
|
| Metaplasia | 1 | 2009 | 326 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2014 | 1137 | 0.020 |
Why?
|
| SEER Program | 1 | 2013 | 1473 | 0.020 |
Why?
|
| Acute Disease | 1 | 2018 | 7245 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 2016 | 873 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1994 | 1895 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 2565 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 208 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 3110 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 1599 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2011 | 658 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2003 | 4850 | 0.020 |
Why?
|
| HIV Infections | 1 | 2014 | 17589 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3811 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 982 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 1640 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 797 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 17174 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 3233 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 521 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 6023 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 419 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2892 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 2008 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6242 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2007 | 564 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2008 | 1609 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4291 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 13427 | 0.010 |
Why?
|
| Psoriasis | 1 | 2012 | 926 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2015 | 2986 | 0.010 |
Why?
|
| Orthopedic Procedures | 1 | 2014 | 1280 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 1769 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 5520 | 0.010 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 1880 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5342 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 2914 | 0.010 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2003 | 15 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 2714 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6888 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1996 | 6001 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 642 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2007 | 910 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2007 | 1439 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2003 | 204 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2008 | 1345 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2007 | 2695 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 5803 | 0.010 |
Why?
|
| Osteonectin | 1 | 2000 | 33 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 3450 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2002 | 663 | 0.010 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 601 | 0.010 |
Why?
|
| Intestines | 1 | 2009 | 1911 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2000 | 277 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8317 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2000 | 320 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 22381 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2019 | 6879 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2231 | 0.010 |
Why?
|
| Drug Costs | 1 | 2006 | 1198 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 4784 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2003 | 965 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2827 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2006 | 3585 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 5035 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1994 | 317 | 0.010 |
Why?
|
| Warfarin | 1 | 2003 | 1493 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 20776 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1994 | 777 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 2646 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 4064 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1994 | 1755 | 0.010 |
Why?
|
| Spleen | 1 | 1994 | 2294 | 0.000 |
Why?
|
| Pilot Projects | 1 | 2000 | 8742 | 0.000 |
Why?
|